{"id":201074,"date":"2024-12-09T18:04:19","date_gmt":"2024-12-10T00:04:19","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2024\/12\/fda-approves-new-cancer-treatments"},"modified":"2024-12-09T18:04:19","modified_gmt":"2024-12-10T00:04:19","slug":"fda-approves-new-cancer-treatments","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2024\/12\/fda-approves-new-cancer-treatments","title":{"rendered":"FDA Approves New Cancer Treatments"},"content":{"rendered":"<p><a class=\"blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/fda-approves-new-cancer-treatments2.jpg\"><\/a><\/p>\n<p>In August, the Food and Drug Administration (FDA) granted accelerated approval of Tecelra (afamitresgene autoleucel)\u2014 the first T-cell receptor therapy for solid tumors\u2014for people with inoperable or metastatic synovial sarcoma. Tecelra is a gene therapy created from a patient\u2019s own T cells. A sample of cells is removed and genetically modified to express a natural T-cell receptor that targets MAGE-A4, an antigen expressed on cancer cells. In the Phase II SPEARHEAD-1 trial, the overall response rate was 43%, and 39% of responders were still doing well a year later.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>In August, the Food and Drug Administration (FDA) granted accelerated approval of Tecelra (afamitresgene autoleucel)\u2014 the first T-cell receptor therapy for solid tumors\u2014for people with inoperable or metastatic synovial sarcoma. Tecelra is a gene therapy created from a patient\u2019s own T cells. A sample of cells is removed and genetically modified to express a natural [\u2026]<\/p>\n","protected":false},"author":511,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,412],"tags":[],"class_list":["post-201074","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-genetics"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/201074","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/511"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=201074"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/201074\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=201074"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=201074"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=201074"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}